Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5NET 3Endocrine 3Sarcoma 2Genitourinary 2Thoracic 1Head & Neck 1Breast 1

Conditions

Carcinoma, Renal Cell 145Kidney Neoplasms 42Prostatic Neoplasms 16Neoplasm Metastasis 16Urinary Bladder Neoplasms 13Neoplasms 9Clear-cell metastatic renal cell carcinoma 6Breast Neoplasms 5Kidney Diseases 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Urologic Neoplasms 3Urogenital Neoplasms 3Urethral Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Gastrointestinal Stromal Tumors 3Carcinoma 3Stomach Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2

Interventions

Sunitinib 2pentetreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Sunitinib × Genitourinary × Clear all
NCT05800106 2023-04-10

A Bioequivalence Study of Sunitinib Malate Capsules.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Completed
24 enrolled
GastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Adenoma, Islet Cell, Gastrointestinal Stromal Tumors

NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡